KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Capital Expenditures (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Capital Expenditures for 15 consecutive years, with $405.0 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Capital Expenditures fell 26.36% year-over-year to $405.0 million, compared with a TTM value of $1.5 billion through Dec 2023, down 34.06%, and an annual FY2024 reading of $1.4 billion, down 5.34% over the prior year.
  • Capital Expenditures was $405.0 million for Q4 2023 at Thermo Fisher Scientific, up from $332.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $831.0 million in Q4 2021 and bottomed at $201.0 million in Q1 2019.
  • Average Capital Expenditures over 5 years is $432.2 million, with a median of $431.5 million recorded in 2023.
  • The sharpest move saw Capital Expenditures soared 148.22% in 2021, then plummeted 43.87% in 2023.
  • Year by year, Capital Expenditures stood at $289.0 million in 2019, then skyrocketed by 102.77% to $586.0 million in 2020, then skyrocketed by 41.81% to $831.0 million in 2021, then tumbled by 33.81% to $550.0 million in 2022, then fell by 26.36% to $405.0 million in 2023.
  • Business Quant data shows Capital Expenditures for TMO at $405.0 million in Q4 2023, $332.0 million in Q3 2023, and $284.0 million in Q3 2023.